Rockville, MD – Sensei Biotherapeutics has announced the acquisition of Faeth Therapeutics (https://www.faeththerapeutics.com/). According to the company announcement, Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Following the acquisition of Faeth Therapeutics, Sensei’s lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors.

To learn more about Sensei Biotherapeutics, visit https://www.senseibio.com/
Company LinkedIn Page: https://www.linkedin.com/company/sensei-bio/

Company Contact:

Sensei Biotherapeutics
1405 Research Blvd Suite 125
Rockville, MD 20850
240-243-8000

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.